Latest Breaking News On - Viability kit - Page 1 : comparemela.com

Science for just $15 USD. Short circuiting solid tumors Two major hurdles in chimeric antigen receptor (CAR) T cell therapy for solid tumors are ensuring specificity to tumor cells without affecting healthy cells and avoiding tumor escape due to antigen loss. To address these challenges, Hyrenius-Wittsten et al. and Choe et al. developed synthetic Notch (synNotch)–CAR T cells targeting solid tumor antigens and used them to treat mouse models of mesothelioma, ovarian cancer, and glioblastoma. In both studies, the authors demonstrated that synNotch-CAR T cells were better at controlling tumors than traditional CAR T cells and did not result in toxicity or damage to healthy tissue. These results suggest that synNotch-CAR T cells may be an effective treatment strategy for solid tumors.

United kingdomTakara bioFacsaria iiiuChan zuckerberg biohubCelltrace violetB ebert addgeneEssen bioscienceP steinberger addgeneSwedish society for medical researchNational cancer instituteTransfection reagent mirus bioKleberg foundationWorthington biochemical corporationSoftware essen bioscienceSwedish research councilCancer research united kingdom